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Bluetongue virus (BTV), the type species of the genus Orbivirus within the family Reoviridae, has a
genome consisting of 10 linear double-stranded RNA genome segments. Current reverse genetics
approaches for engineering the BTV genome rely upon in vitro synthesis of capped RNA transcripts from
cloned cDNA corresponding to viral genome segments. In an effort to expand the utility of BTV reverse
genetics, we constructed a reverse genetics vector containing a T7 RNA polymerase promoter, hepatitis
delta ribozyme sequence and T7 RNA polymerase terminator sequence. Viable virus was recovered fol-
lowing transfection of mammalian cells, expressing T7 RNA polymerase, with 10 plasmid constructs
representing the cloned BTV-1 genome. Furthermore, the plasmid-based reverse genetics system was
used successfully to isolate viable cross-serotype reassortant viruses and a mutant virus containing a
deﬁned mutation in the replicating viral genome. The new reverse genetics platform established here for
BTV is likely applicable to other orbiviruses.
& 2015 Elsevier Inc. All rights reserved.Introduction
Bluetongue virus (BTV), an arbovirus transmitted by a few
species of biting midges of the genus Culicoides, is the causative
agent of bluetongue disease of domesticated and wild ruminants.
Among domestic species, sheep is the most susceptible and most
severely affected host, but cattle and wild ruminants serve as
reservoirs for the virus (Wilson and Mellor, 2009). Bluetongue
disease is endemic in many parts of the world, including Africa
and some regions of Asia, Australia and America (Walton, 2004;
MacLachlan, 2011). However, there have been increasingly fre-
quent outbreaks in European countries due to a northern expan-
sion of the virus, with several outbreaks also occurring in the
Balkans (Purse et al., 2005; Mellor et al., 2008; MacLachlan and
Guthrie, 2010). Due to its severity, economic impact and ability to
spread rapidly from endemic regions, bluetongue disease is listed
by the World Organization for Animal Health (OIE) as a notiﬁable
disease of livestock.
BTV is a member of the Orbivirus genus in the Reoviridae family
and has a genome consisting of 10 segments of linear double-
stranded RNA (dsRNA), designated from segment 1 (S1) to S10 in
decreasing order of size (Verwoerd et al., 1970). The viral genome).encodes seven structural proteins and four non-structural proteins
(NS1–NS4) (Roy, 2007; Belhouchet et al., 2011; Ratinier et al., 2011).
Structural proteins VP1, VP3, VP4, VP6 and VP7 form the virus core
particle, which is surrounded by an outer capsid layer composed of
VP2 and VP5 (Verwoerd et al., 1972). Shortly after cell entry by the
virus, the outer capsid proteins are removed and the transcriptionally
active core particle is released into the host cell cytoplasm. Within the
core particle, each of the dsRNA genome segments is repeatedly
transcribed by the core-associated enzymes VP1 (RNA-dependent
RNA polymerase), VP4 (capping enzyme) and VP6 (helicase), resulting
in extrusion of newly synthesized, capped, viral single-stranded RNA
(ssRNA). The extruded transcripts, in turn, function as templates for
the synthesis of viral proteins and also act as templates for the
synthesis of genomic dsRNA following their encapsidation in progeny
viral cores (Mertens and Diprose, 2004; Patel and Roy, 2014).
The development of reverse genetics systems for all major
groups of RNA- and DNA-containing viruses is considered to be
one of the most transformative technological advances in virology,
having allowed for considerable progress to be made in under-
standing multiple aspects of virus biology and pathogenesis.
Despite variations in their molecular design and methodology,
these reverse genetics systems all share a common feature, which
is the availability of cloned cDNA copies of the viral genomes that
can be genetically modiﬁed and manipulated to generate live
viruses containing precisely engineered changes in their genomes
(Bridgen, 2012). In contrast to other RNA viruses, the construction
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has proven to be challenging, owing in part to the technical
complexity of manipulating multi-segmented genomes (Komoto
and Taniguchi, 2013; Trask et al., 2013). Reoviruses, which contain
a 10-segmented dsRNA genome, were the ﬁrst members of the
Reoviridae family for which a plasmid-based reverse genetics
method was developed (Kobayashi et al., 2007). This was followed
by the establishment of reverse genetics systems for different
members of the genus Orbivirus such as BTV (Boyce et al., 2008;
Matsuo and Roy, 2013), African horse sickness virus (Kaname et al.,
2013) and, more recently, epizootic hemorrhagic disease virus
(Yang et al., 2015). In contrast to the plasmid-based reverse
genetics system established for reovirus, the reverse genetics
systems developed for the above orbiviruses all rely on the use of
in vitro-synthesized and capped T7 RNA transcripts from cloned
cDNAs corresponding to viral genomic segments. In this approach,
permissive cells are transfected with expression helper plasmids
that synthesize the inner core proteins and two non-structural
proteins (NS1 and NS2), followed by transfection of the cells with
all 10 synthetic T7 transcripts.
Here we describe the establishment of an entirely plasmid-
based reverse genetics system for the prototype orbivirus, BTV, in
which viable virus was generated solely from cDNA clones. The
performance of this system was validated by isolation of a viable
mutant virus containing a targeted marker mutation introduced
into the viral genome, as well as viable directed cross-serotype
reassortant viruses.Results
Construction of a T7 RNA polymerase-based reverse genetics plasmid
It has been demonstrated previously that transfection of per-
missive cells with message-sense RNA synthesized in vitro from
core particles of different orbiviruses leads to the production of
viral progeny (Boyce and Roy, 2007; Matsuo et al., 2010). These
data would suggest that an entirely plasmid DNA-based reverseFig. 1. Experimental strategy to generate BTV from cloned cDNAs. (A) Diagram of the pR
genome segment cDNA is driven by an upstream T7 RNA polymerase promoter, producin
native 30-terminal sequences through the autocatalytic cleavage of an HDV ribozyme se
genome segment transcription cassette, are transfected into T7 RNA polymerase-expres
positive-sense RNAs that serve as templates for protein synthesis and genome replicatigenetics system for orbiviruses would be feasible if the transcripts
produced from the recombinant plasmids mimicked the viral
message-sense RNAs. To this end, we engineered a reverse
genetics vector, designated pRG15, as described under Materials
and Methods. The pRG15 vector contains a BsmBI cloning site
ﬂanked by an upstream T7 RNA polymerase promoter sequence
and downstream hepatitis delta virus ribozyme (HDVR) and T7
RNA polymerase terminator sequences (Fig. 1A). Considering that
the T7 RNA polymerase promoter directs transcription initiation
preferentially from a juxtaposed guanosine residue (Milligan et al.,
1987) and that all BTV message-sense RNAs are terminated with a
5' guanosine (Rao et al., 1983), plasmid-generated transcripts were
thus expected to possess native 5' ends (Fig. 1A). Moreover, self-
cleavage of the HDV ribozyme fused to the 3' terminus of nascent
transcripts is anticipated to generate RNAs with native BTV 3'
termini (Fig. 1A). Plasmid transfection of BSR cells in which T7 RNA
polymerase is constitutively expressed (Fig. 1B) should therefore
yield 10 unique BTV mRNA species that are capable of serving as
templates for viral protein synthesis and negative-strand synthesis
to form the dsRNA genome segments present in progeny virus
particles.
Generation of viable BTV-1 from cDNA plasmids
To determine whether infectious BTV could be generated with
the plasmid-based reverse genetics vector system, cDNA copies of
each BTV-1 genome segment were cloned into the pRG15 reverse
genetics vector. The 10 BTV-1 constructs were co-transfected in T7
RNA polymerase-expressing BSR-T7 cells. The cells were harvested
at 3–5 days post-transfection, lysed and plaque assays were per-
formed. In contrast to mock-transfected cells, plaques were
recovered from cells transfected with the 10 BTV-1 cDNA plasmids
(Fig. 2A). The viral titers in transfection lysates were 1.4104 pfu/
ml and 9.1105 pfu/ml at 3 days and 5 days post-transfection,
respectively. To conﬁrm virus recovery, viruses from individual
plaques were ampliﬁed, after which dsRNA was extracted and
analyzed by non-denaturing polyacrylamide gel electrophoresis.
The electrophoresis pattern of dsRNA segments extracted fromG15 reverse genetics vector. In each recombinant plasmid, transcription of the BTV
g transcripts with a native 50-terminal sequence. The transcripts are equipped with
quence. (B) To generate BTV, the 10 recombinant plasmids, each harboring a BTV
sing BSR-T7 cells. Cytoplasmic transcription of the cloned cDNAs yields native BTV
on, resulting in the recovery of infectious virions.
Fig. 2. Recovery of infectious BTV-1 by transfection of BSR-T7 cells with 10 cDNA
plasmids. (A) Plaque assay of the transfection cell lysate performed at 72 h post-
transfection (well 2). Mock-transfected cells (well 1) were included as a control.
(B) Electropherotypes of wild-type (WT) BTV-1 and plasmid-derived recombinant
BTV-1 (lanes 1–3). Genomic dsRNA were electrophoresed in an 8.5% non-dena-
turing polyacrylamide gel, followed by ethidium bromide staining to visualize the
viral genome segments (S1–S10).
Fig. 3. Characterization of recombinant BTV-1 containing a mutation and recom-
binant cross-serotype reassortant viruses. (A and B) RT-PCR products of the S8
genome segment of wild-type (WT) BTV-1 and recombinant mutant BTV-1 (Mut)
were analyzed by agarose gel electrophoresis after digestion of the products with
XhoI (A), and the nucleotide sequence of the RT-PCR products were also determined
and compared (B). Shown in (B) is the sequence chromatogram demonstrating the
presence of the introduced T to C and G to C point mutations, resulting in an XhoI
silent mutation. (C) Electropherotypes of the recombinant reassortant viruses
B1BTV-10VP2 (lane 1) and B1BTV-10VP2/VP5 (lane 2) obtained by electrophoresis of
the genomic dsRNA in an 8.5% non-denaturing polyacrylamide gel. The reassortant
viruses contain respectively genome segment S2 from BTV-10 and both genome
segments S2 and S5 from BTV-10 in an otherwise BTV-1 genetic background.
Arrows indicate the slower migrating BTV-10 S2 (lane 1) and S2 and S5 (lane 2)
genome segments. Wild-type BTV-1 dsRNA and BTV-10 dsRNA marker lanes are
indicated to the left and right of the ﬁgure, respectively.
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1 derived from cell infection (Fig. 2B). The complete nucleotide
sequence of plasmid-derived BTV-1 was also determined and
matched that of the parental plasmids (data not shown). Thus,
BTV, like reovirus, can be recovered from plasmid cDNAs expres-
sing full-length positive-sense RNAs without the need for syn-
thetic transcripts or helper plasmids that express viral proteins
independently (Kobayashi et al., 2007).
Generation of directed mutant and reassortant viruses
To determine whether the plasmid-based reverse genetics
system is sufﬁciently robust to enable the introduction of a speciﬁc
mutation into the BTV genome, a unique XhoI restriction enzyme
site was incorporated into the S8 genome segment of BTV-1 by the
introduction of two silent point mutations into the pRG15-B1-S8
rescue plasmid: T to C at nucleotide 635 and G to C at nucleotide
637. BSR-T7 cells were subsequently co-transfected with the
recombinant pRG15 reverse genetics plasmids in which the wild-
type pRG15-B1-S8 construct was substituted with the mutant
pRG15-B1-S8mut plasmid. Viruses resulting from the transfection
were plaque-puriﬁed and dsRNA extracted from virus-infected
BSR cells were used for cDNA synthesis. To conﬁrm that the
viruses contain the introduced mutation, the S8 genome segment
was PCR ampliﬁed, digested with XhoI and the reaction mixtures
analyzed by agarose gel electrophoresis. The results indicated that,
in contrast to the non-mutated S8 genome segment which was not
cleaved by the restriction enzyme, the S8 genome segment of
mutant BTV-1 was cleaved and yielded two DNA fragments of the
expected sizes (635 and 490 base pairs) (Fig. 3A). The nucleotide
sequences of the puriﬁed amplicons were also determined, theresults of which conﬁrmed the presence of the unique XhoI
restriction enzyme site (Fig. 3B).
We next attempted to modify the BTV-1 genome by exchanging
the S2 or both the S2 and S5 genome segments of BTV-1 with
those of BTV-10. These genome segments encode for the outer
capsid proteins VP2 and VP5, respectively (Boyce et al., 2008). For
this purpose, cDNA copies of the S2 and S5 genome segments from
BTV-10 were cloned into the pRG15 reverse genetics plasmid to
yield pRG15-B10-S2 and pRG15-B10-S5, respectively. BSR-T7 cells
were subsequently co-transfected with mixtures of plasmid DNA
in which pRG15-B10-S2 or both pRG15-B10-S2 and pRG15-B10-S5
were used to substitute the corresponding BTV-1 rescue plasmids.
Reassortant viruses from randomly selected plaques were ampli-
ﬁed in BSR cells, dsRNA was extracted and the genotype of the
recovered viruses was initially determined by electrophoresis of
the dsRNA on non-denaturing polyacrylamide gels. The electro-
phoretic pattern of a representative monoreassortant, B1BTV-
10VP2, which contains the BTV-10 S2 genome segment in an
otherwise BTV-1 background, clearly shows co-migration of the S2
RNA with that of BTV-10. Likewise, the double-reassortant virus
B1BTV-10VP2/VP5 displayed an electropherotype consistent with
eight genome segments derived from BTV-1 and two genome
segments, S2 and S5, derived from BTV-10 (Fig. 3C). The identity of
the S2 and S5 genome segments as originating from BTV-10 was
Fig. 4. Virus growth curves. BSR cells were infected with wild-type (WT) BTV-1,
plasmid-derived BTV-1 (rgBTV-1) and the reassortant viruses B1BTV-10VP2 and
B1BTV-10VP2/VP5 at a MOI of 0.1 pfu/cell, and viral titers were determined by plaque
assay at the times shown. Results are presented as the mean viral titers for four
experiments and error bars indicate the standard deviation.
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respective genome segments (data not shown).
Growth properties of wild-type and recombinant viruses in mam-
malian cells
The replicative capacities of wild-type BTV-1 and plasmid-
derived BTV-1 (hereafter designated wtBTV-1 and rgBTV-1,
respectively) as well as the reassortant viruses B1BTV-10VP2 and
B1BTV-10VP2/VP5 were evaluated in BSR cells. Cells were infected
with each indicated virus at a multiplicity of infection (MOI) of
0.1 pfu/cell and virus titers were determined at various time points
post-infection. Essentially no difference in growth kinetics was
observed between wtBTV-1 and rgBTV-1. The double-reassortant
virus B1BTV-10VP2/VP5 grew slightly slower than wtBTV-1 or
rgBTV-1 until 36 h post-infection, but reached a peak titer of
3.5107 pfu/ml at 72 h post-infection which is similar to that of
wtBTV-1 and rgBTV-1 (Fig. 4). In contrast, the monoreassortant
virus B1BTV-10VP2 achieved lower titers than any of the other
viruses at each time point. Although the peak titer of B1BTV-10VP2
was 1.6107 pfu/ml at 72 h post-infection, this was approximately
2.1-fold lower than the other viruses included in the assay (Fig. 4).Discussion
Current methods for engineering the segmented dsRNA gen-
omes of orbiviruses, including BTV, are limited to the use of RNA-
based reverse genetics systems, in which virus is recovered wholly
from in vitro-synthesized capped T7 transcripts or, alternatively, by
transfecting the full complement of capped synthetic T7 tran-
scripts into cells previously transfected with helper expression
plasmids to form the primary replication complex (Boyce et al.,
2008; Matsuo and Roy, 2013; Kaname et al., 2013; Yang et al.,
2015). In an effort to expand the utility of BTV reverse genetics, our
objective in this study was to develop an unencumbered reverse
genetics platform to recover recombinant BTV from plasmid
cDNA only.
We constructed a reverse genetics vector, pRG15, into which
cDNA of each BTV-1 genome segment was cloned. The cloned
cDNA is ﬂanked by a T7 RNA polymerase promoter sequence at the
5' end, and a HDV ribozyme and T7 RNA polymerase terminator atthe 3' end. This strategy for the synthesis of BTV-1 mRNA species
was aimed at overcoming problems inherent to the in vitro
synthesis of T7 run-off transcripts. T7 RNA polymerase introduces
considerable heterogeneity on the 3' end of the transcripts. Not
only does premature termination of transcription produce shor-
tened transcripts, but also the enzyme tends to add a few extra
nucleotides at the 3' end of the transcript that are not present in
the linearized DNA template (Milligan et al., 1987; Martin et al.,
1988) and, in certain cases, may produce RNAs that are longer than
expected (Cazenave and Uhlenbeck, 1994). Indeed, recovery of
infectious BTV from 10 synthetic T7 transcripts was reported to be
less efﬁcient compared to the use of core-derived viral transcripts
(Boyce et al., 2008). Thus, incorporation of the cis-acting HDV
ribozyme into the RNAs transcribed directly from the plasmid-
borne cDNA copies of the viral genome segments should overcome
the above problems by producing transcripts with homogenous 3'
ends (Schürer et al., 2002). Transfection of the 10 BTV-1 rescue
plasmids into the cytoplasm of T7 RNA polymerase-expressing BSR
cells consistently resulted in the recovery of recombinant BTV-1.
Growth kinetics, total yield and the genomic electrophoretic sig-
nature were indistinguishable between wild-type BTV-1 and the
recombinant BTV-1, thus validating retention of the native viral
properties by the plasmid-derived viruses.
Although RNAs transcribed directly from the recombinant
plasmids will not contain a 5' cap, the recovery of infectious BTV
from plasmid cDNA alone demonstrates that the transcripts syn-
thesized are functionally equivalent to authentic viral transcripts
at all stages of the replication cycle. The transcripts are translated
and selected during packaging and mediate negative-strand
synthesis, resulting in infectious virions. These results are in
accordance with those reported for reovirus, which indicated that
recombinant reovirus could be recovered following transfection of
BHK cells constitutively expressing T7 RNA polymerase with four
rescue plasmids corresponding to the reovirus genome (Kobayashi
et al., 2010). In this regard, it is interesting to note that Fuerst and
Moss (1989) reported that uncapped and non-polyadenylated T7
transcripts originating from plasmids transfected into mammalian
cells had a half-life of 75 min and represented up to 30% of the
total cytoplasmic RNA after a 24-h period. Thus, the sustained
synthesis of RNA transcripts and their accumulation to relatively
high levels in the cell cytoplasm may account for the efﬁciency in
BTV rescue. Indeed, at 3 days post-transfection, plasmid-derived
BTV-1 reached a titer of 1.4104 pfu/ml.
To evaluate the utility of the fully plasmid-based BTV reverse
genetics system, we successfully generated a mutant BTV-1 con-
taining a deﬁned mutation in the replicating viral genome. This
reverse genetics platform can therefore be used to introduce
mutations into targeted proteins as a means to elucidate struc-
ture–function relationships in viral proteins and furthermore
provides an opportunity to observe the effects of these mutations
on BTV biology in the context of a replicating virus. We subse-
quently used the reverse genetics platform to generate reassortant
viruses in which the VP2 protein or both the VP2 and VP5 outer
capsid proteins of BTV-1 were replaced with those of BTV-10.
Growth kinetics of the reassortant viruses indicated that the
monoreassortant virus B1BTV-10VP2 produced a lower titer than
that of wild-type BTV-1, whereas the double reassortant virus
B1BTV-10VP2/VP5 replicated to the same titer than wild-type BTV-1.
In mammalian cells, BTV enters the cell through receptor-
mediated endocytosis and is incorporated into early endosomes
(Forzan et al., 2007). The outermost capsid protein VP2 is the
cellular receptor binding protein, whereas VP5 is a membrane-
penetrating protein that is thought to permeabilize the endosomal
membrane, thereby releasing the transcriptionally active core-
particle into the cell cytoplasm (Hassan et al., 2001; Zhang et al.,
2010). Whether the observed growth difference is therefore due to
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may inﬂuence the receptor binding ability of VP2 or subsequent
uncoating of the virus prior to release of the core particle into the
cytoplasm requires further investigation. It is clear, however, that
the plasmid-based reverse genetics system can be used to gen-
erate directed reassortant viruses. As such, the reverse genetics
system can be exploited to generate directed reassortant viruses to
investigate BTV virulence and pathogenicity (Coetzee et al., 2014;
Celma et al., 2014), in addition to generating “serotyped” vaccine
viruses (van Gennip et al., 2012; Feenstra et al., 2014; Nunes et al.,
2014).
In conclusion, the entirely plasmid-based BTV reverse genetics
system described here provides a new platform to augment
existing platforms and has the added advantages of reduced
reagent preparation time and expense. This could facilitate and
accelerate basic studies of BTV biology, including aspects per-
taining to replication, transmission, pathogenesis and immunity.
Considering that orbiviruses have similar virion structures and
replication mechanisms, the principles and techniques established
in this study may be applied to the development of similar
plasmid-based reverse genetics systems for other members of the
Orbivirus genus.Materials and methods
Cells and viruses
BSR cells (a clone of BHK-21 cells) were cultured at 37 °C and
5% CO2 in Minimum essential medium (Eagle's MEM) supple-
mented with 2 mM L-glutamine, Earle's balanced salt solution
(Lonza), 1% (v/v) non-essential amino acids (HyClone), 5% (v/v)
fetal bovine serum (FBS) and antibiotics (10,000 U/ml penicillin G,
10,000 U/ml streptomycin, 25 mg/ml amphotericin B) (HyClone).
BSR-T7 cells, which stably express bacteriophage T7 RNA poly-
merase (Buchholz et al., 1999), were maintained in the same
manner as BSR cells except for the addition of 1 mg/ml of Genet-
icin (Invitrogen) with every second passage of the BSR-T7 cells.
Both BSR and BSR-T7 cells are highly permissive for BTV growth.
BTV serotypes 1 (BTV-1) and 10 (BTV-10) were used for cell
infections. BSR cell monolayers were rinsed twice with incomplete
EMEM (lacking FBS and antibiotics) and then infected with virus at
a multiplicity of infection (MOI) of 0.1 pfu/cell. Virus adsorptions
were performed at 37 °C for 1 h, followed by incubation of the cell
monolayers in complete EMEM for 3–4 days.
Construction of the pRG15 reverse genetics vector
The pRG15 reverse genetics vector was constructed in three
stages. In the ﬁrst stage, oligonucleotides were assembled to yield
a transcription cassette comprising a T7 RNA polymerase pro-
moter, followed by two inverted BsmBI restriction enzyme sites, a
hepatitis delta virus ribozyme (HDVR) sequence and a T7 RNA
polymerase terminator sequence (Fig. 1A). Oligonucleotides RG-F1
through RG-R6 (Supplementary Table S1) were 51–64 nt in length
and conﬁgured in such a way that, upon assembly, complementary
oligonucleotides overlap by at least 20 nucleotides. The 5'-phos-
phorylated oligonucleotides were purchased from Inqaba Bio-
technical Industries, re-suspended in sterile 10 mM Tris (pH 8) and
stored at 80 °C. For oligonucleotide assembly, an overlap-
extension PCR was performed (Stemmer et al., 1995). Brieﬂy,
500 nM of the outer oligonucleotides (RG-F1 and RG-R6) and
25 nM of the internal oligonucleotides (RG-R2, RG-F3, RG-R4 and
RG-F5) were added to a PCR reaction mixture containing 1 U of
Phusion High-Fidelity DNA Polymerase (Thermo Scientiﬁc), 1HF
buffer and 200 mM each of dNTP. The reaction was subjected to aninitial denaturation step of 98 °C for 10 s, followed by 30 cycles of
98 °C for 20 s, 58 °C for 30 s and 72 °C for 30 s. The 257-bp product
was puriﬁed from an agarose gel and cloned into pSMART LC Amp
(Lucigen), according to the manufacturer's instructions, to yield
pSMART-T7C. In the second stage, the reverse genetics vector
backbone was prepared. To this end, pUC19 was used as the
template in an inverse PCR reaction with primers ver2F and ver2R
(Supplementary Table S1) to remove the lacZ' region inclusive of
the multiple cloning site, as well as two BsmBI restriction enzyme
sites present on the pUC19 backbone. Finally, the transcription
cassette was excised from pSMART-T7C with EcoRV and blunt-end
ligated to the modiﬁed pUC19 genetic backbone to produce the
reverse genetics vector pRG15. The nucleotide sequence of the
cloned insert DNA was veriﬁed by automated sequencing proce-
dures using the ABI PRISM BigDye Terminator Cycle Sequencing
Ready Reaction kit v3.1 (Perkin-Elmer Applied Biosystems).
Cloning of BTV-1 cDNA
Total RNA was extracted from BTV-1-infected BSR cells with
Tri-Reagent (Sigma-Aldrich) and ssRNA was subsequently
removed by precipitation with 2 M LiCl and centrifugation at
17,000g for 15 min at 4 °C. First-strand cDNAwas synthesized from
5 mg of dsRNA using the RevertAid H Minus First Strand cDNA
Synthesis kit (Thermo Scientiﬁc) according to the manufacturer's
protocol. cDNA copies of each BTV-1 genome segment were
ampliﬁed by PCR using appropriate primer pairs (Supplementary
Table S1) and Phusion High-Fidelity DNA Polymerase (Thermo
Scientiﬁc). Puriﬁed full-length PCR products were digested with
BsmBI (S1, S2, S3, S8 and S9 cDNA), BbsI (S4, S6, S7 and S10 cDNA)
or BspMI (S5 cDNA) and ligated into BsmBI-digested plasmid
pRG15. The derived recombinant plasmids were named pRG15-B1-
S1 through pRG15-B1-S10. The complete nucleotide sequences of
the cDNA clones were determined and exactly matched the
database sequences (GenBank accession nos FJ969719-FJ969728;
Boyce et al., 2008).
Construction of plasmids for use in targeted mutagenesis and reas-
sortant experiments
Using a similar approach to that described above, reverse
genetics plasmid clones were constructed for BTV-10 genome
segment 2 (pRG15-B10-S2) and genome segment 5 (pRG15-B10-
S5). Segment-speciﬁc cDNAs were ampliﬁed by PCR using primers
B10VP2F and B10VP2R for S2, and primers B10VP5F and B10VP5R
for S5 (Supplementary Table S1).
A mutant version of the BTV-1 S8 genome segment, containing an
introduced XhoI restriction enzyme recognition sequence, was con-
structed by a megaprimer PCR-based mutagenesis strategy in which
three primers and two PCRs were used (Sarkar and Sommer, 1990). In
the ﬁrst round of PCR, pRG15-B1-S8 was used as the template together
with primer B1NS2R and the internal mutagenic primer NS2-mut
(Supplementary Table S1). The puriﬁed amplicon was then used as a
‘megaprimer’ along with primer B1NS2F in the second round of PCR to
generate the full-length S8 genome segment containing the newly
introduced mutations. The PCR product was puriﬁed from an agarose
gel, digested with BsmBI and then cloned into the BsmBI site of pRG15
to generate pRG15-B1-S8mut. The mutation inserted in the modiﬁed
pRG15-B1-S8 plasmid was conﬁrmed by nucleotide sequencing.
Plasmid transfections and recovery of infectious virus
Plasmid DNA used in cell transfections was puriﬁed with the
GeneJET plasmid midiprep kit (Thermo Scientiﬁc), inclusive of the
endotoxin removal procedure, according to the manufacturer's
instructions. For recovery of BTV-1 from the plasmid cDNA clones,
monolayers of BSR-T7 cells at 50% conﬂuence in 25-cm2 tissue
culture ﬂasks were co-transfected with the 10 recombinant pRG15
plasmid constructs representing the cloned BTV-1 genome using
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1.1 mg of each recombinant plasmid was mixed in an Eppendorf
tube, then diluted in 1.1 ml of OptiMEM I Reduced Serum Medium
(Life Technologies) and 11 ml of PLUS Reagent (Life Technologies)
was added. Following a 5-min incubation at room temperature,
28 ml of Lipofectamine LTX reagent was added and incubation was
continued for 45 min at room temperature. The transfection
mixture was added to BSR-T7 cells and OptiMEM I Reduced Serum
Medium was added to a ﬁnal volume of 3 ml. Four hours later, 5%
(v/v) FBS was added to the medium. The same protocol was used
for recovery of mutant BTV-1, except that pRG15-B1-S8 was sub-
stituted with the pRG15-B1-S8mut recombinant plasmid prior to
transfection of the BSR-T7 cell monolayer. To recover directed
reassortant BTV, the BSR-T7 cells were likewise co-transfected
with a mixture consisting of the pRG15-B1 recombinant plasmids
in which the pRG15-B1-S5 and/or pRG15-B1-S2 plasmids were
substituted with recombinant plasmids pRG15-B10-S5 and/or
pRG15-B10-S2, respectively. Following incubation of the trans-
fected cells until the marked cytopathic effect (CPE) was observed
(typically 3 days post-transfection), recombinant virus was iso-
lated from the transfected cells by plaque puriﬁcation on BSR cells
(Oellermann, 1970).
Identiﬁcation of plasmid-derived mutant and reassortant viruses
To identify mutant BTV-1, PCR ampliﬁcation of synthesized
cDNAwas performed with the S8 genome segment-speciﬁc primer
pair. The amplicons were subjected to XhoI restriction endonu-
clease digestion, followed by analysis of the digestion products on
an agarose gel. As a ﬁnal conﬁrmation, the nucleotide sequence of
the ampliﬁed S8 genome segments was also determined. To
identify BTV reassortants, puriﬁed viral dsRNA samples were
analyzed using non-denaturing 8.5% polyacrylamide gels. In
addition, cDNA was synthesized from the viral dsRNA and PCR
ampliﬁcation was performed using S2 and S5 genome segment-
speciﬁc primer pairs for BTV-10. The puriﬁed PCR products were
subjected to nucleotide sequencing.
Virus growth curves
Conﬂuent BSR cell monolayers in 6-well tissue culture plates
were infected with wild-type BTV-1, plasmid-derived BTV-1 or
cross-serotype reassortant BTV at a MOI of 0.1 pfu/cell. At different
time points post-infection, the virus titers were determined by
serial dilution and plaque assays on BSR cells.Acknowledgments
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